These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 29713762)

  • 1. Prolonged survival in secondary glioblastoma following local injection of targeted alpha therapy with
    Krolicki L; Bruchertseifer F; Kunikowska J; Koziara H; Królicki B; Jakuciński M; Pawlak D; Apostolidis C; Mirzadeh S; Rola R; Merlo A; Morgenstern A
    Eur J Nucl Med Mol Imaging; 2018 Jul; 45(9):1636-1644. PubMed ID: 29713762
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and efficacy of targeted alpha therapy with
    Królicki L; Bruchertseifer F; Kunikowska J; Koziara H; Królicki B; Jakuciński M; Pawlak D; Apostolidis C; Mirzadeh S; Rola R; Merlo A; Morgenstern A
    Eur J Nucl Med Mol Imaging; 2019 Mar; 46(3):614-622. PubMed ID: 30498897
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Locoregional Treatment of Glioblastoma With Targeted α Therapy: [ 213 Bi]Bi-DOTA-Substance P Versus [ 225 Ac]Ac-DOTA-Substance P-Analysis of Influence Parameters.
    Królicki L; Kunikowska J; Bruchertseifer F; Kuliński R; Pawlak D; Koziara H; Rola R; Morgenstern A; Merlo A
    Clin Nucl Med; 2023 May; 48(5):387-392. PubMed ID: 36854309
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Towards Facile Radiolabeling and Preparation of Gallium-68-/Bismuth-213-DOTA-[Thi
    Suthiram J; Ebenhan T; Marjanovic-Painter B; Sathekge MM; Zeevaart JR
    Pharmaceutics; 2021 Aug; 13(9):. PubMed ID: 34575402
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dose escalation study of targeted alpha therapy with [
    Królicki L; Bruchertseifer F; Kunikowska J; Koziara H; Pawlak D; Kuliński R; Rola R; Merlo A; Morgenstern A
    Eur J Nucl Med Mol Imaging; 2021 Oct; 48(11):3595-3605. PubMed ID: 33860346
    [TBL] [Abstract][Full Text] [Related]  

  • 6.
    Królicki L; Kunikowska J; Bruchertseifer F; Koziara H; Królicki B; Jakuciński M; Pawlak D; Rola R; Morgenstern A; Rosiak E; Merlo A
    Semin Nucl Med; 2020 Mar; 50(2):141-151. PubMed ID: 32172799
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tachykinin Receptor-Selectivity of the Potential Glioblastoma-Targeted Therapy, DOTA-[Thi
    Suthiram J; Pieters A; Mohamed Moosa Z; Zeevaart JR; Sathekge MM; Ebenhan T; Anderson RC; Newton CL
    Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768456
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro evaluation of
    Majkowska-Pilip A; Rius M; Bruchertseifer F; Apostolidis C; Weis M; Bonelli M; Laurenza M; Królicki L; Morgenstern A
    Chem Biol Drug Des; 2018 Jul; 92(1):1344-1356. PubMed ID: 29611298
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-Term Results of Targeted Low-Grade Glioma Treatment with
    Cordier D; Merlo A
    Cancer Biother Radiopharm; 2019 Aug; 34(6):413-416. PubMed ID: 30844298
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeted alpha-radionuclide therapy of functionally critically located gliomas with 213Bi-DOTA-[Thi8,Met(O2)11]-substance P: a pilot trial.
    Cordier D; Forrer F; Bruchertseifer F; Morgenstern A; Apostolidis C; Good S; Müller-Brand J; Mäcke H; Reubi JC; Merlo A
    Eur J Nucl Med Mol Imaging; 2010 Jul; 37(7):1335-44. PubMed ID: 20157707
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neoadjuvant targeting of glioblastoma multiforme with radiolabeled DOTAGA-substance P--results from a phase I study.
    Cordier D; Forrer F; Kneifel S; Sailer M; Mariani L; Mäcke H; Müller-Brand J; Merlo A
    J Neurooncol; 2010 Oct; 100(1):129-36. PubMed ID: 20217458
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of different neurokinin-1 receptor (NK1R) isoforms in glioblastoma multiforme: potential implications for targeted therapy.
    Cordier D; Gerber A; Kluba C; Bauman A; Hutter G; Mindt TL; Mariani L
    Cancer Biother Radiopharm; 2014 Jun; 29(5):221-6. PubMed ID: 24552486
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-Term Tumor Control Following Targeted Alpha Therapy (TAT) of Low-Grade Gliomas (LGGs): A New Treatment Paradigm?
    Krolicki L; Kunikowska J; Cordier D; Slavova N; Koziara H; Bruchertseifer F; Maecke HR; Morgenstern A; Merlo A
    Int J Mol Sci; 2023 Oct; 24(21):. PubMed ID: 37958683
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of recurrent glioblastoma multiforme with GliaSite brachytherapy.
    Chan TA; Weingart JD; Parisi M; Hughes MA; Olivi A; Borzillary S; Alahakone D; Detorie NA; Wharam MD; Kleinberg L
    Int J Radiat Oncol Biol Phys; 2005 Jul; 62(4):1133-9. PubMed ID: 15990019
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stereotactic radiosurgery (SRS): treatment option for recurrent glioblastoma multiforme (GBM).
    Combs SE; Widmer V; Thilmann C; Hof H; Debus J; Schulz-Ertner D
    Cancer; 2005 Nov; 104(10):2168-73. PubMed ID: 16220556
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Progression-free and overall survival in patients with recurrent Glioblastoma multiforme treated with last-line bevacizumab versus bevacizumab/lomustine.
    Heiland DH; Masalha W; Franco P; Machein MR; Weyerbrock A
    J Neurooncol; 2016 Feb; 126(3):567-75. PubMed ID: 26614518
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Application of Neurokinin-1 Receptor in Targeted Strategies for Glioma Treatment. Part I: Synthesis and Evaluation of Substance P Fragments Labeled with
    Majkowska-Pilip A; Koźmiński P; Wawrzynowska A; Budlewski T; Kostkiewicz B; Gniazdowska E
    Molecules; 2018 Oct; 23(10):. PubMed ID: 30301182
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II study of bevacizumab and temsirolimus combination therapy for recurrent glioblastoma multiforme.
    Lassen U; Sorensen M; Gaziel TB; Hasselbalch B; Poulsen HS
    Anticancer Res; 2013 Apr; 33(4):1657-60. PubMed ID: 23564811
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patupilone (epothilone B) for recurrent glioblastoma: clinical outcome and translational analysis of a single-institution phase I/II trial.
    Oehler C; Frei K; Rushing EJ; McSheehy PM; Weber D; Allegrini PR; Weniger D; Lütolf UM; Knuth A; Yonekawa Y; Barath K; Broggini-Tenzer A; Pruschy M; Hofer S
    Oncology; 2012; 83(1):1-9. PubMed ID: 22688083
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II trial of temozolomide plus the matrix metalloproteinase inhibitor, marimastat, in recurrent and progressive glioblastoma multiforme.
    Groves MD; Puduvalli VK; Hess KR; Jaeckle KA; Peterson P; Yung WK; Levin VA
    J Clin Oncol; 2002 Mar; 20(5):1383-8. PubMed ID: 11870183
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.